- Previous Close
0.2600 - Open
0.7000 - Bid 1.0900 x 300
- Ask 1.2500 x 300
- Day's Range
0.5700 - 1.5510 - 52 Week Range
0.2400 - 3.1630 - Volume
491,440,955 - Avg. Volume
902,558 - Market Cap (intraday)
19.645M - Beta (5Y Monthly) 3.14
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
www.bioaffinitytech.com75
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BIAF
View MorePerformance Overview: BIAF
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIAF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIAF
View MoreValuation Measures
Market Cap
4.70M
Enterprise Value
5.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.30
Price/Book (mrq)
1.51
Enterprise Value/Revenue
0.60
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-90.16%
Return on Assets (ttm)
-62.34%
Return on Equity (ttm)
-167.00%
Revenue (ttm)
9.37M
Net Income Avi to Common (ttm)
-8.45M
Diluted EPS (ttm)
-0.8000
Balance Sheet and Cash Flow
Total Cash (mrq)
756.58k
Total Debt/Equity (mrq)
55.09%
Levered Free Cash Flow (ttm)
-3.71M